Suppr超能文献

针对 CD133 的免疫毒素的光化学内化 (PCI) 在具有癌症干细胞特性的细胞中具有特异性,在皮摩尔水平下具有高效力。

Photochemical internalization (PCI) of immunotoxins targeting CD133 is specific and highly potent at femtomolar levels in cells with cancer stem cell properties.

机构信息

Department of Radiation Biology, Institute for Cancer Research, Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway.

出版信息

J Control Release. 2013 Jun 28;168(3):317-26. doi: 10.1016/j.jconrel.2013.03.023. Epub 2013 Apr 6.

Abstract

CD133 is a putative cancer stem cell (CSC) marker for a number of different cancers and is suggested to be a therapeutic target. Since also normal stem cells express CD133 it is of paramount importance that targeting strategies provide a specific and efficient delivery of cytotoxic drugs in only CD133-positive CSCs. In this study, we have employed photochemical internalization (PCI), a minimally invasive method for light-controlled, specific delivery of membrane-impermeable macromolecules from endocytic vesicles to the cytosol, to specifically target CD133-positive cancer cells. We demonstrate that PCI increases the cytotoxic effect of an immunotoxin (IT) targeting CD133-expressing cancer cells of colon (WiDr and HCT116) and pancreas (BxPC-3) origin. The IT consisted of the mAb CD133/1 (AC133) bound to the ribosome inactivating plant toxin saporin (anti-CD133/1-sap). We show that TPCS2a-PCI of anti-CD133/1-sap is specific, and highly cytotoxic at femto-molar concentrations. Specific binding and uptake of CD133/1, was shown by fluorescence microscopy and co-localization with TPCS2a in endosomes/lysosomes was determined by confocal microscopy. CD133(high) WiDr cells, isolated by fluorescence activated cell sorting, had a 7-fold higher capacity to initiate spheroids than CD133(low) cells (P<0.001) and were resistant to photodynamic therapy (PDT). However, PDT-resistance was bypassed by the PCI strategy. Tumor initiation and aggressive growth in athymic nude mice was obtained with only 10 CD133(high) cells in contrast to CD133(low) cells where substantially higher cell numbers were needed. The excellent high efficacy and selectivity of eliminating CD133-expressing cells by PCI warrant further pre-clinical evaluations of this novel therapeutic approach.

摘要

CD133 是多种不同癌症的假定癌症干细胞 (CSC) 标志物,被认为是一个治疗靶点。由于正常干细胞也表达 CD133,因此至关重要的是,靶向策略能够特异性和有效地将细胞毒性药物递送至仅 CD133 阳性的 CSCs 中。在这项研究中,我们采用了光化学内化 (PCI),这是一种微创方法,可用于将膜不可渗透的大分子从内吞体特异性递送至细胞质中,以特异性靶向 CD133 阳性癌细胞。我们证明,PCI 增加了针对结肠 (WiDr 和 HCT116) 和胰腺 (BxPC-3) 起源的表达 CD133 的癌细胞的免疫毒素 (IT) 的细胞毒性作用。该 IT 由与核糖体失活植物毒素丝裂霉素 (抗-CD133/1-sap) 结合的 mAb CD133/1 (AC133) 组成。我们表明,TPCS2a-PCI 抗-CD133/1-sap 是特异性的,并且在飞摩尔浓度下具有高度细胞毒性。通过荧光显微镜观察到 CD133/1 的特异性结合和摄取,并通过共聚焦显微镜确定了与 TPCS2a 在内涵体/溶酶体中的共定位。通过荧光激活细胞分选分离的 CD133(high) WiDr 细胞比 CD133(low) 细胞具有 7 倍更高的启动球体的能力 (P<0.001),并且对光动力疗法 (PDT) 具有抗性。然而,PCI 策略绕过了 PDT 抗性。仅用 10 个 CD133(high) 细胞即可在免疫缺陷裸鼠中获得肿瘤起始和侵袭性生长,而 CD133(low) 细胞则需要更高的细胞数。通过 PCI 策略消除表达 CD133 的细胞的高效性和选择性非常出色,这保证了这种新的治疗方法的进一步临床前评估。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验